Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

LivaNova to Announce Second-Quarter 2022 Results


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second-quarter 2022 results on Wednesday, August 3, 2022 at 1 p.m. London time (8 a.m. EDT). The Company will release its second-quarter 2022 results prior to the call.

A live audiocast of the conference call will be available on the LivaNova website at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 844 200 6205 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 469820. A replay will be available on the LivaNova website for 90 days following the call.

About LivaNova

LivaNova PLC is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 3,000 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. For more information, please visit www.livanova.com.

Safe Harbor Statement

This news release contains "forward-looking statements" concerning the Company's goals, beliefs, expectations, strategies, objectives, plans and underlying assumptions and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding the next Company conference call. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company's most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.


These press releases may also interest you

at 18:40
Qualitrol are excited to announce QualConnex, our latest innovation in wireless cloud-based monitoring. QualConnex is being released...

at 18:23
Novavax, Inc. , a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Novavax...

at 17:30
Akili, a leading digital medicine company, today completed its previously announced business combination with Social Capital Suvretta Holdings Corp. I ("SCS") , a publicly traded special purpose acquisition company. The newly formed company, Akili,...

at 17:06
Radiance Technologies (Radiance) has been awarded a prime contract with the National Air and Space Intelligence Center (NASIC) to provide scientific and technical intelligence support services under the NOVASTAR program. The multiple-award,...

at 17:05
Eddy Smart Home Solutions Ltd. (formerly Aumento Capital VIII Corp.) ("Eddy" or the "Company") today announced that after revisiting its interpretation and application of certain technical accounting standards related to non-cash consideration...

at 17:00
DeepMarkit Corp., ("DeepMarkit" or the "Company") (FRA: DEP), a company focused on transitioning the global carbon offset market to the more accessible digital economy by minting carbon offsets onto the blockchain, announces that it has granted an...



News published on 22 june 2022 at 09:05 and distributed by: